XASXZNO
Market cap5mUSD
Dec 23, Last price
0.03AUD
1D
4.00%
1Q
13.04%
Name
Zoono Group Ltd
Chart & Performance
P/E
—
P/S
10.62
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.87%
Rev. gr., 5y
-11.23%
Revenues
960k
Net income
0k
CFO
-3m
Dividend
Sep 04, 20200.03 AUD/sh
Earnings
Feb 20, 2025
Profile
Zoono Group Limited, together with its subsidiaries, engages in the research, development, and sale of a range of antimicrobial products in New Zealand and internationally. The company's products include hand sanitizers, textile applicators, mould remediation, and surface sanitizers. It serves airlines, healthcare, childcare, facilities management, transportation, education, and hospitality sectors. The company was incorporated in 1986 and is headquartered in Auckland, New Zealand.
Valuation
Title NZD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | ||||||||||
Revenues | 960 | 9,328 -65.53% | ||||||||
Cost of revenue | 2,958 | 13,197 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (1,998) | (3,868) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | (1,998) | (3,868) | ||||||||
Net income | (11,791) -367.70% | |||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 4,124 | 219 | ||||||||
BB yield | -72.31% | -1.05% | ||||||||
| Debt | ||||||||||
Debt current | 148 | 141 | 164 | |||||||
Long-term debt | 1,305 | 727 | 1,887 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,257 | 6,122 | ||||||||
Net debt | (342) | 868 | (1,601) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (3,163) | |||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | 3,986 | |||||||||
FCF | 2,320 | 3,062 | 384 | |||||||
| Balance | ||||||||||
Cash | 1,795 | 3,653 | ||||||||
Long term investments | ||||||||||
Excess cash | 1,747 | 3,186 | ||||||||
Stockholders' equity | 18,141 | 13,731 | 14,200 | |||||||
Invested Capital | 6,481 | 13,399 | 14,179 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 219,370 | 168,893 | 167,179 | |||||||
Price | 0.03 -31.58% | 0.04 -69.60% | 0.13 -79.51% | |||||||
Market cap | 5,704 -11.13% | 6,418 -69.29% | 20,897 -79.48% | |||||||
EV | 5,362 | 7,286 | 19,296 | |||||||
EBITDA | (1,783) | (3,548) | ||||||||
EV/EBITDA | ||||||||||
Interest | 72 | 77 | ||||||||
Interest/NOPBT | ||||||||||